Detalhe da pesquisa
1.
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Cancer
; 129(14): 2256-2265, 2023 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37151113
2.
Interleukin 1 level, cognitive performance, and severity of depressive symptoms in patients treated with systemic anticancer therapy: a prospective study.
Croat Med J
; 60(2): 166-173, 2019 Apr 30.
Artigo
Inglês
| MEDLINE | ID: mdl-31044590
3.
Beyond PD-L1 Markers for Lung Cancer Immunotherapy.
Int J Mol Sci
; 20(8)2019 Apr 18.
Artigo
Inglês
| MEDLINE | ID: mdl-31003463
4.
Population morbidity in elderly lung cancer patients from Poland with specific trends in elderly women.
Prz Menopauzalny
; 18(3): 161-165, 2019 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-31975983
5.
MicroRNA-126 selected with broad-spectrum analysis of microRNAs - a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients?
Front Immunol
; 15: 1344858, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38469304
6.
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
Lung Cancer
; 193: 107821, 2024 May 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38820979
7.
Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice.
Front Oncol
; 14: 1341084, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38322415
8.
Double Guard Efficiency and Safety-Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients.
Cancers (Basel)
; 15(13)2023 Jul 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37444609
9.
Guidelines for the diagnosis and management of osteoporosis in Poland. Update 2022.
Endokrynol Pol
; 74(1): 5-15, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36847720
10.
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
J Thorac Oncol
; 18(6): 755-768, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37001859
11.
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in Poland: analysis of patient series and practical guidelines for breast surgeons.
Arch Med Sci
; 19(5): 1243-1251, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37732037
12.
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
J Thorac Oncol
; 18(11): 1594-1606, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37390980
13.
Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients.
Cancers (Basel)
; 14(22)2022 Nov 14.
Artigo
Inglês
| MEDLINE | ID: mdl-36428677
14.
RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.
Cancers (Basel)
; 14(21)2022 Oct 27.
Artigo
Inglês
| MEDLINE | ID: mdl-36358717
15.
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Nat Med
; 28(11): 2374-2380, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36008722
16.
Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients.
Cancers (Basel)
; 13(6)2021 Mar 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33799560
17.
Viral Infection and Lung Cancer Immunotherapy.
Front Oncol
; 11: 577514, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34434887
18.
Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer-Clinical Trials Experience.
Cancers (Basel)
; 13(20)2021 Oct 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34680195
19.
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry.
Target Oncol
; 16(3): 357-367, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33826036
20.
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
J Clin Oncol
; 39(26): 2914-2925, 2021 09 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34255535